Real-world experience of Fuzheng Yiqing granule as chemoprophylaxis against COVID-19 infection among close contacts: A prospective cohort study

IF 3.6 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of Evidence‐Based Medicine Pub Date : 2024-04-09 DOI:10.1111/jebm.12591

Qianzi Che, Ruili Huo, Chen Zhao, Wei Yang, Xinghua Xiang, Shihuan Tang, Jiaheng Shi, Cheng Lu, Hongmei Li, Luqi Huang

{"title":"Real-world experience of Fuzheng Yiqing granule as chemoprophylaxis against COVID-19 infection among close contacts: A prospective cohort study","authors":"Qianzi Che, Ruili Huo, Chen Zhao, Wei Yang, Xinghua Xiang, Shihuan Tang, Jiaheng Shi, Cheng Lu, Hongmei Li, Luqi Huang","doi":"10.1111/jebm.12591","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The objective of the current study was to evaluate whether the use of traditional Chinese medicine, Fuzheng Yiqing granule (FZYQG), was associated with a reduced infection risk of COVID-19 in close contacts.</p>\n </section>\n \n <section>\n \n <h3> Research design and methods</h3>\n \n <p>This was a prospective cohort study across 203 quarantine centres for close contacts and secondary contacts of COVID-19 patients in Yangzhou city. FZYQG group was defined as quarantined individuals who voluntarily took FZYQG; control group did not take FZYQG. The primary outcome was the coronavirus test positive rate during quarantine period. Logistic regression with propensity score inverse probability weighting was used for adjusted analysis to evaluate independent association between FZYQG and test positive rate.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From July 13, 2021 to September 30, 2021, 3438 quarantined individuals took FZYQG and 2248 refused to take the granule. Test positive rate was significantly lower among quarantined individuals who took FZYQG (0.29% vs. 1.73%, risk ratio 0.17, 95% confidence interval (CI): 0.08–0.34, <i>p</i> < 0.001). On logistic regression, odds for test positive were decreased in FZYQG group (odds ratio: 0.16, 95% CI: 0.08–0.32, <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Close and secondary contacts of COVID-19 patients who received FZYQG had a lower test positive rate than control individuals in real-world experience.</p>\n </section>\n \n <section>\n \n <h3> Trial registration</h3>\n \n <p>This study has been registered on Chinese Clinical Trial Registry (ChiCTR2100049590) on August 5, 2021.</p>\n </section>\n </div>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":"17 2","pages":"269-277"},"PeriodicalIF":3.6000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Evidence‐Based Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jebm.12591","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The objective of the current study was to evaluate whether the use of traditional Chinese medicine, Fuzheng Yiqing granule (FZYQG), was associated with a reduced infection risk of COVID-19 in close contacts.

Research design and methods

This was a prospective cohort study across 203 quarantine centres for close contacts and secondary contacts of COVID-19 patients in Yangzhou city. FZYQG group was defined as quarantined individuals who voluntarily took FZYQG; control group did not take FZYQG. The primary outcome was the coronavirus test positive rate during quarantine period. Logistic regression with propensity score inverse probability weighting was used for adjusted analysis to evaluate independent association between FZYQG and test positive rate.

Results

From July 13, 2021 to September 30, 2021, 3438 quarantined individuals took FZYQG and 2248 refused to take the granule. Test positive rate was significantly lower among quarantined individuals who took FZYQG (0.29% vs. 1.73%, risk ratio 0.17, 95% confidence interval (CI): 0.08–0.34, p < 0.001). On logistic regression, odds for test positive were decreased in FZYQG group (odds ratio: 0.16, 95% CI: 0.08–0.32, p < 0.001).

Conclusions

Close and secondary contacts of COVID-19 patients who received FZYQG had a lower test positive rate than control individuals in real-world experience.

Trial registration

This study has been registered on Chinese Clinical Trial Registry (ChiCTR2100049590) on August 5, 2021.

查看原文本刊更多论文

将扶正益青颗粒作为预防密切接触者感染 COVID-19 的化学预防药物的实际经验：前瞻性队列研究。

研究背景本研究旨在评估使用中药扶正益青颗粒（FZYQG）是否与降低密切接触者感染COVID-19的风险有关：这是一项前瞻性队列研究，涉及扬州市203个COVID-19患者密切接触者和二次接触者检疫中心。FZYQG组定义为自愿服用FZYQG的被隔离者；对照组不服用FZYQG。主要结果是检疫期间冠状病毒检测阳性率。采用倾向得分反概率加权的逻辑回归进行调整分析，以评估 FZYQG 与检测阳性率之间的独立关联：从 2021 年 7 月 13 日至 2021 年 9 月 30 日，3438 名被检疫者服用了 FZYQG，2248 名被检疫者拒绝服用颗粒剂。服用 FZYQG 的被检疫者检测阳性率明显降低（0.29% vs. 1.73%，风险比 0.17，95% 置信区间 (CI)：0.08-0.34，P 结论：COVID 密切接触者和二次接触者的检测阳性率明显降低：在真实世界中，接受FZYQG治疗的COVID-19患者的密切接触者和二次接触者的检测阳性率低于对照组：本研究已于2021年8月5日在中国临床试验注册中心注册（ChiCTR2100049590）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Evidence‐Based Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

11.20

自引率

1.40%

发文量

期刊介绍： The Journal of Evidence-Based Medicine (EMB) is an esteemed international healthcare and medical decision-making journal, dedicated to publishing groundbreaking research outcomes in evidence-based decision-making, research, practice, and education. Serving as the official English-language journal of the Cochrane China Centre and West China Hospital of Sichuan University, we eagerly welcome editorials, commentaries, and systematic reviews encompassing various topics such as clinical trials, policy, drug and patient safety, education, and knowledge translation.